

Silvio Bellino

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5532949/silvio-bellino-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62
papers

1,208
citations

19
h-index

33
g-index

69
ext. papers

1,455
ext. citations

5
avg, IF

4.55
L-index

#	Paper	IF	Citations
62	The Impact of SARS-CoV-2 Infection on Youth Mental Health: A Narrative Review.. <i>Biomedicines</i> , 2022 , 10,	4.8	4
61	The relative contributions of insight and neurocognition to intrinsic motivation in schizophrenia.. <i>NPJ Schizophrenia</i> , 2022 , 8, 18	5.5	
60	Borderline Personality Disorder: Risk Factors and Early Detection. <i>Diagnostics</i> , 2021 , 11,	3.8	2
59	Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset. <i>Diagnostics</i> , 2021 , 11,	3.8	2
58	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2021 , 1-9	3.8	1
57	Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
56	Accuracy of self-assessment of real-life functioning in schizophrenia. <i>NPJ Schizophrenia</i> , 2021 , 7, 11	5.5	4
55	Pharmacological Treatment for Social Cognition: Current Evidence. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
54	The Role of Trauma in Early Onset Borderline Personality Disorder: A Biopsychosocial Perspective. <i>Frontiers in Psychiatry</i> , 2021 , 12, 721361	5	3
53	Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough?. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 47-61	4	16
52	The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. <i>World Psychiatry</i> , 2020 , 19, 81-91	14.4	37
51	Trauma and psychopathology associated with early onset BPD: an empirical contribution. <i>Journal of Psychiatric Research</i> , 2020 , 131, 54-59	5.2	4
50	Interpersonal Psychotherapy as a Single Treatment for Borderline Personality Disorder: A Pilot Randomized-Controlled Study. <i>Frontiers in Psychiatry</i> , 2020 , 11, 578910	5	1
49	Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
48	Models Predicting Psychosis in Patients With High Clinical Risk: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2020 , 11, 223	5	7
47	Early Detection and Outcome in Borderline Personality Disorder. <i>Frontiers in Psychiatry</i> , 2019 , 10, 710	5	18
46	Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2019 , 10, 67	5	35

45	Autobiographical memories, identity disturbance and brain functioning in patients with borderline personality disorder: An fMRI study. <i>Heliyon</i> , 2019 , 5, e01323	3.6	13
44	Effectiveness of psychosocial treatments on symptoms and functional domains in schizophrenia spectrum disorders: a prospective study in a real-world setting. <i>Disability and Rehabilitation</i> , 2019 , 41, 2799-2806	2.4	0
43	Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	18
42	Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. <i>Clinical Drug Investigation</i> , 2019 , 39, 169-178	3.2	5
41	Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study. <i>Clinical Drug Investigation</i> , 2018 , 38, 367-372	3.2	13
40	The Italian Version of the Borderline Personality Disorder Severity Index IV: Psychometric Properties, Clinical Usefulness, and Possible Diagnostic Implications. <i>Journal of Personality Disorders</i> , 2018 , 32, 207-219	2.6	2
39	Treatment-induced brain plasticity in borderline personality disorder: review of functional MRI studies. <i>Future Neurology</i> , 2018 , 13, 225-238	1.5	0
38	Unblending Borderline Personality and Bipolar Disorders. <i>Journal of Psychiatric Research</i> , 2017 , 91, 90-97	5.2	14
37	Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2017 , 13, 2767-2779	3.1	16
36	Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial. <i>CNS Drugs</i> , 2017 , 31, 809-819	6.7	17
35	Pharmacotherapy of personality disorders: what we know and what we have to search for. <i>Future Neurology</i> , 2017 , 12, 199-222	1.5	3
34	Treating Depression: What Patients Want; Findings From a Randomized Controlled Trial in Primary Care. <i>Psychosomatics</i> , 2016 , 57, 616-623	2.6	7
33	Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. <i>Journal of Clinical Medicine</i> , 2016 , 5,	5.1	93
32	Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: A two-years follow-up. <i>Psychiatry Research</i> , 2016 , 240, 151-156	9.9	17
31	Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. <i>Psychiatry Research</i> , 2015 , 226, 284-8	9.9	13
30	Interpersonal Psychotherapy Adapted for Borderline Personality Disorder (IPT-BPD): A Review of Available Data and a Proposal of Revision 2015 , 05,		3
29	Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder. <i>Molecular Diagnosis and Therapy</i> , 2014 , 18, 567-77	4.5	14
28	Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. <i>Journal of Psychopharmacology</i> , 2014 , 28, 125-32	4.6	38

27	No effect of serotonergic gene variants on response to interpersonal counseling and antidepressants in major depression. <i>Psychiatry Investigation</i> , 2013 , 10, 180-9	3.1	18
26	Antipsychotics in the Treatment of Impulsivity in Personality Disorders and Impulse Control Disorders. <i>Current Psychopharmacology</i> , 2012 , 2, 5-17	0.6	1
25	New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder. <i>Current Psychopharmacology</i> , 2012 , 1, 86-96	0.6	
24	Quality of life of patients who undergo breast reconstruction after mastectomy: effects of personality characteristics. <i>Plastic and Reconstructive Surgery</i> , 2011 , 127, 10-17	2.7	35
23	Recent approaches to pharmacotherapy of personality disorders. <i>Neuropsychiatry</i> , 2011 , 1, 259-273	1.8	3
22	Pharmacotherapy of borderline personality disorder: a systematic review for publication purpose. <i>Current Medicinal Chemistry</i> , 2011 , 18, 3322-9	4.3	15
21	Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability. <i>Depression Research and Treatment</i> , 2011 , 2011, 680194	3.8	9
20	Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. <i>Journal of Psychopharmacology</i> , 2010 , 24, 333-9	4.6	23
19	Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. <i>Canadian Journal of Psychiatry</i> , 2010 , 55, 74-81	4.8	28
18	Efficacy and tolerability of pharmacotherapies for borderline personality disorder. <i>CNS Drugs</i> , 2008 , 22, 671-92	6.7	34
17	Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. <i>Psychiatry Research</i> , 2008 , 161, 206-12	9.9	14
16	Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. <i>Canadian Journal of Psychiatry</i> , 2007 , 52, 718-25	4.8	26
15	Dysmorphic concern symptoms and personality disorders: a clinical investigation in patients seeking cosmetic surgery. <i>Psychiatry Research</i> , 2006 , 144, 73-8	9.9	62
14	Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. <i>Canadian Journal of Psychiatry</i> , 2006 , 51, 453-60	4.8	49
13	Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1042-6	4.6	43
12	Depressive and negative symptoms in schizophrenia: different effects on clinical features. <i>Comprehensive Psychiatry</i> , 2005 , 46, 304-10	7.3	56
11	Clinical picture of obsessive-compulsive disorder with poor insight: a regression model. <i>Psychiatry Research</i> , 2005 , 136, 223-31	9.9	64
10	Major depression in patients with borderline personality disorder: a clinical investigation. <i>Canadian Journal of Psychiatry</i> , 2005 , 50, 234-8	4.8	32

9	Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 1111-5	4.6	36
8	Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 908-14	4.6	39
7	Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. <i>CNS Drugs</i> , 2002 , 16, 273-83	6.7	50
6	Clinical features of dysthymia and age: a clinical investigation. <i>Psychiatry Research</i> , 2001 , 103, 219-28	9.9	6
5	Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. <i>Psychiatry Research</i> , 2000 , 96, 91-8	9.9	97
4	Recognition and treatment of dysthymia in elderly patients. <i>Drugs and Aging</i> , 2000 , 16, 107-21	4.7	8
3	Long Term Treatment of Obsessive-Compulsive Disorder. <i>CNS Drugs</i> , 1998 , 10, 247-255	6.7	12
2	An open-label, randomized, prospective comparison of sertraline and amisulpride in the treatment of dysthymia in the elderly. <i>Current Therapeutic Research</i> , 1997 , 58, 798-808	2.4	9
1	Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment. <i>Psychiatry Research</i> , 1995 , 57, 49-56	9.9	8